Drug Profile


Alternative Names: 5 amino acid β-sheet breaker peptide; Amyloid inhibiting peptides; iAβ5; β-Sheet breaker peptide

Latest Information Update: 28 Jan 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator New York University; TorreyPines Therapeutics Inc
  • Class
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 23 Feb 2004 Discontinued - Phase-I for Alzheimer's disease in Switzerland (unspecified route)
  • 24 Apr 2003 Phase-I clinical trials in Alzheimer's disease in Switzerland (unspecified route)
  • 29 Nov 2001 A preclinical study has been added to the pharmacodynamics and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top